- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Horizon Pharma Makes Another Bid for Depomed
July 21, 2015.
Horizon Pharma (Dublin, Ireland) has again raised its offer to buy Depomed Inc (Newark, CA). Horizon is now offering $33 (£21.2) per share, contingent on the smaller drugmaker agreeing to start takeover talks, Reuters reports. The equity value of the new offer works out to $1.97 billion, according to Thomson Reuters calculations. Horizon Pharma previously made an offer of $29.25 per share (about $1.74 billion) but Depomed refused to engage in talks. Horizon then raised its offer to $32.25 per share, which was again rejected earlier this week. http://uk.reuters.com/article/2015/07/21/uk-depomed-m-a-horizon-phar-idUKKCN0PV19J20150721
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.
